Inhibitors of BRAF dimers using an allosteric site

BRAF kinase, a critical effector of the ERK signaling pathway, is hyperactivated in many cancers. Oncogenic BRAF(V600E) signals as an active monomer in the absence of active RAS, however, in many tumors BRAF dimers mediate ERK signaling. FDA-approved RAF inhibitors poorly inhibit BRAF dimers, which...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Commun
Autors principals: Cotto-Rios, Xiomaris M., Agianian, Bogos, Gitego, Nadege, Zacharioudakis, Emmanouil, Giricz, Orsi, Wu, Yang, Zou, Yiyu, Verma, Amit, Poulikakos, Poulikos I., Gavathiotis, Evripidis
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7462985/
https://ncbi.nlm.nih.gov/pubmed/32873792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-18123-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars